COG2 and atherosclerosis: Nowadays, the pattern of targeting LDL-C alone has changed, with recent guidelines highlighting the importance of non-high-density lipoprotein cholesterol (non-HDL-C), which includes RLP-C, on the pathogenesis of atherosclerosis and thus its availability as an additional therapeutic target [11].